See What HealthDay Can Do For You
Contact Us

Novel Chemotherapies More Often Used On- Than Off-Label

Off-label use, accounting for 30 percent, conforms to NCCN-supported indications in ~half of cases

Novel Chemotherapies More Often Used On- Than Off-Label

MONDAY, Feb. 25 (HealthDay News) -- In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label, according to a study published online Feb. 19 in the Journal of Clinical Oncology.

To examine the prevalence of off-label use of 10 commonly prescribed patent-protected anticancer drugs, Rena M. Conti, Ph.D., of the University of Chicago, and colleagues analyzed prescribing data from a pharmacy software provider maintaining a population-based cohort database including 570 medical oncologists in 122 medical oncology practices.

The researchers found that 70 percent of chemotherapy use was on-label, and 30 percent was off-label. Fourteen percent of chemotherapy use conformed to an off-label indication supported by the National Comprehensive Care Network (NCCN) recommendations. Ten percent of off-label use occurred at a U.S. Food and Drug Administration-approved cancer site but for a stage of cancer or line of therapy that was not recommended by the NCCN. Spending on these chemotherapies amounted to $2 billion for off-label and NCCN supported uses and $2.5 billion for off-label and NCCN unsupported uses, compared with $7.3 billion for on-label uses.

"The overall proportion of off-label use that the authors identified is not high, especially when taking into account NCCN-approved indications, but the variation by drug and the associated costs are high," write the authors of an accompanying editorial. "The ultimate goal should not be zero off-label prescribing, but rather that the entire system be designed to maximize the likelihood of an optimal risk-benefit ratio for both individual patients and the system as a whole."

One author disclosed financial ties to Genentech; a second author is an economic expert for plaintiffs in suit against the manufacturer of rituximab.

Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.